Immuneering (IMRX) Enterprise Value (2020 - 2024)
Immuneering (IMRX) has 5 years of Enterprise Value data on record, last reported at -$50.7 million in Q3 2024.
- For Q3 2024, Enterprise Value rose 47.91% year-over-year to -$50.7 million; the TTM value through Sep 2024 reached -$50.7 million, up 47.91%, while the annual FY2023 figure was -$85.7 million, 18.82% up from the prior year.
- Enterprise Value reached -$50.7 million in Q3 2024 per IMRX's latest filing, up from -$59.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$37.1 million in Q4 2020 and bottomed at -$149.5 million in Q3 2021.
- Average Enterprise Value over 5 years is -$96.0 million, with a median of -$97.2 million recorded in 2023.
- Peak YoY movement for Enterprise Value: crashed 302.26% in 2021, then surged 47.91% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$37.1 million in 2020, then tumbled by 302.26% to -$149.2 million in 2021, then grew by 29.27% to -$105.5 million in 2022, then grew by 18.82% to -$85.7 million in 2023, then soared by 40.87% to -$50.7 million in 2024.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$50.7 million in Q3 2024, -$59.7 million in Q2 2024, and -$71.3 million in Q1 2024.